Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women–Perspectives in the Management of Type 2 Diabetes
Biomolecules · 2023
DOI: 10.3390/biom13111602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Magdalena Wiecek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biochemistry, University of Physical Education in Kraków, 31-571 Kraków, Poland. Hauptthemen laut MEDLINE: Cryotherapy, Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education under the name "Regional Initiative for Perfection" within the years 2019-2022, University of Physical Education in Kraków (Poland), programme of the Ministry of Science and Higher Education.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes (T2DM) is a global problem. The effect of whole-body cryotherapy (WBC) on metabolism in humans is postulated. The aim of this study was to determine the effect of WBC on asprosin concentrations, glucose homeostasis and insulin resistance in postmenopausal women with T2DM. Changes in fasting blood glucose (FBG), glycated haemoglobin (HbA1c), insulin, asprosin, insulin-resistance indices (HOMA-IR, Quicki), the triglyceride–glucose index (TyG) and C-reactive protein (CRP) were determined. Determination was carried out after 30 WBCs (3 min, −120 °C), applied in six series of five treatments, with 2-day breaks in postmenopausal women with T2DM and the results were compared to changes in postmenopausal women without T2DM (CON). Blood was collected before 1 WBC (T0), after 30 WBCs (T1) and 2 weeks after their completion (T2). In the T2DM group, there was a significant decrease in FBG and HbA1c in T1 and T2, as well as a significant decrease in insulin, HOMA-IR and CRP, and an increase in the Quicki index in T2. In the CON group, the concentration of asprosin at T2 was significantly lower than at T0. There was a significantly positive correlation between asprosin and FBG and HOMA-IR, and a trend towards a decrease of asprosin concentration in T2 in postmenopausal women with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biochemistry, University of Physical Education in Kraków, 31-571 Kraków, Poland.
- Department of Clinical Rehabilitation, University of Physical Education in Kraków, 31-571 Kraków, Poland.
- Laboratory of Biochemistry and Molecular Biology, University of Physical Education in Kraków, 31-571 Kraków, Poland.
- Department of Sports Medicine and Human Nutrition, University of Physical Education in Kraków, 31-571 Kraków, Poland.
ORCID-Profile: Magdalena Wiecek, Jadwiga Szymura, Justyna Kusmierczyk, Maria Lipowska
Förderung
- Ministry of Science and Higher Education under the name "Regional Initiative for Perfection" within the years 2019-2022
- University of Physical Education in Kraków (Poland)
- programme of the Ministry of Science and Higher Education
Zitieren
APA
Wiecek, M., Szymura, J., Kusmierczyk, J., Lipowska, M., & Szygula, Z. (2023). Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women–Perspectives in the Management of Type 2 Diabetes. Biomolecules. https://doi.org/10.3390/biom13111602
Vancouver
Wiecek M, Szymura J, Kusmierczyk J, Lipowska M, Szygula Z. Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women–Perspectives in the Management of Type 2 Diabetes. Biomolecules. 2023. doi:10.3390/biom13111602
BibTeX
@article{Wiecek2023,
author = {Wiecek, Magdalena and Szymura, Jadwiga and Kusmierczyk, Justyna and Lipowska, Maria and Szygula, Zbigniew},
title = {Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women–Perspectives in the Management of Type 2 Diabetes},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13111602}
}
EUVIMED